Business Context and Reporting Period
This Form 8-K was filed by Bio-Rad Laboratories, Inc. on January 9, 2007. The report addresses a corporate governance issue regarding the company's continued listing status on the American Stock Exchange (Amex).
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a listing compliance matter and does not contain financial performance data.
Material Changes
The material change reported is a failure to satisfy a continued listing standard due to a reduction in the number of independent directors on the Audit Committee. Specifically, the death of Mr. Philip L. Padou left the committee with only two independent directors, whereas the Amex Company Guide requires three.
Outlook, Risks, and Contingencies
- Compliance Deadline: The Amex granted the company until April 9, 2007 to regain compliance.
- Management Action: The company is actively seeking a replacement for Mr. Padou to serve on the Board of Directors and Audit Committee.
- Current Status: The Amex issued a "Warning Letter" but determined not to apply immediate continued listing evaluation and follow-up procedures.
- Risk of Delisting: Failure to resolve the deficiency by the April 9, 2007 deadline could result in the assessment of continued listing eligibility and/or the initiation of delisting proceedings.
Key Facts for Investor Verification
- Verify the appointment of a new independent director to the Audit Committee before the April 9, 2007 deadline.
- Confirm the company's continued listing status on the American Stock Exchange.
- Review the referenced Press Release (Exhibit 99.1) dated January 12, 2007, for additional management commentary.